Arrowhead Pharmaceuticals has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics to develop ...

Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, ...

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...

Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...

Analyst Kostas Biliouris of BMO Capital reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

William Blair analyst Sami Corwin has maintained their bullish stance on SRPT stock, giving a Buy rating today.Don't Miss our Black Friday ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

Roche announced it will acquire Poseida Therapeutics in a deal worth up to $1.5 Billion. The deal allows the Swiss company to ...

Arrowhead Pharmaceuticals is a biotechnology company focused on developing RNA interference (RNAi) therapeutics. Their proprietary platform, Targeted RNAi Molecule (TRiM™), allows them to target and ...

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...